Veno-occlusive disease: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
Line 13: | Line 15: | ||
==Diagnosis== | ==Diagnosis== | ||
===Symptoms=== | ===Symptoms=== | ||
*[[Weight gain]] | |||
*[[Right upper quadrant pain]] due to [[hepatomegaly]] | |||
*[[Abdominal swelling]] due to [[ascites]] | |||
===Physical Examination=== | |||
Tender [[hepatomegaly]], [[ascites]], and increased [[bilirubin]]. It often is associated with [[renal failure]]. | |||
==Pathophysiology== | ==Pathophysiology== |
Revision as of 15:38, 3 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and Keywords: VOD, sinuosoidal obstruction syndrome
Overview
Veno-occlusive disease (VOD) is a disease affecting the liver. VOD is a complication that occurs in up to 25% of bone marrow transplantations, and may also occur after ingestion of certain plant alkaloids.
Prognosis
When associated with bone marrow transplant, VOD is fatal in over 30% of cases. Cases due to plant alkaloids often have a longer and more unpredictable course.
Diagnosis
Symptoms
Physical Examination
Tender hepatomegaly, ascites, and increased bilirubin. It often is associated with renal failure.
Pathophysiology
In the BMT setting, VOD is felt to due to injury to the hepatic venous endothelium from the conditioning regimen. It is also known as sinuosoidal obstruction syndrome.
Treatment
Treatment for VOD is primarily supportive. In the BMT setting, defibrotide is an investigational treatment that may be promising. Defibrotide is a polydeoxyribonucleotide; its mechanism of benefit in VOD is unclear, but has been attributed to its antithromboitc properties.
Sources
Kumar, V., Abbas, A. and N. Fausto. 2004. Robbins & Cotran Pathologic Basis of Disease. Philadelphia: W. B. Saunders Company.
References
External link
- American Society of Hematology education book discussion of VOD